Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 5/20 | 0.39 |
| ▸ | ACE | P12821 | 5/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17287153 | 0.94 | PTGS1 (0.57) | PTGS1GSTK1MAPTPTGS2BLM | |
| SCHEMBL4424322 | 0.93 | MAPT (0.60) | PTGS1GSTK1MAPTPTGS2BLM | |
| SCHEMBL18263621 | 0.93 | MAPT (0.60) | PTGS1GSTK1MAPTPTGS2BLM | |
| SCHEMBL4632742 | 0.90 | MAPT (0.56) | PTGS1GSTK1MAPTPTGS2BLM | |
| SCHEMBL20787749 | 0.83 | PTGS1 (0.67) | PTGS1GSTK1MAPTPTGS2BLM | |
| SCHEMBL236405 | 0.83 | PTGS1 (0.67) | PTGS1GSTK1MAPTPTGS2BLM | |
| SCHEMBL12442747 | 0.82 | KDM4E (0.53) | PTGS1GSTK1MAPTPTGS2BLM | |
| SCHEMBL29774451 | 0.82 | PTGS1 (0.52) | PTGS1GSTK1MAPTPTGS2BLM | |
| SCHEMBL26819626 | 0.81 | PTGS1 (0.62) | PTGS1GSTK1MAPTPTGS2BLM | |
| SCHEMBL30589370 | 0.81 | PTGS1 (0.62) | PTGS1GSTK1MAPTPTGS2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551549-B2 | Methods of eliciting antibodies that bind to full-length glycosylated HIV-1 ENV using multimerized ENV cores | FRED HUTCHINSON CANCER CENTER (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260041758-A1 | IMMUNIZATION STRATEGIES TO MORE NATURALLY GUIDE THE MATURATION OF ANTIBODIES AGAINST HUMAN IMMMUNODEFICIENCY VIRUS (HIV) IN HIV-INFECTED SUBJECTS | FRED HUTCHINSON CANCER CENTER (US) | 2026-02-12 | — | — | US | disclosed |
| WO-2025137325-A1 | IMMUNIZATION SCHEDULES TO ELICIT BROADLY-NEUTRALIZING ANTIBODIES AGAINST HUMAN IMMMUNODEFICIENCY VIRUS (HIV) | FRED HUTCHINSON CANCER CENTER (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20240238405-A1 | METHODS OF ELICITING ANTIBODIES THAT BIND TO FULL-LENGTH GLYCOSYLATED HIV-1 ENV USING MULTIMERIZED ENV CORES | FRED HUTCHINSON CANCER CENTER (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240075121-A1 | CIRCUMSPOROZOITE PROTEINS WITH INCREASED EXPRESSION IN MAMMALIAN CELLS | FRED HUTCHINSON CANCER CENTER (US) | 2024-03-07 | — | — | US | disclosed |
| WO-2024036217-A2 | IMMUNIZATION STRATEGIES TO MORE NATURALLY GUIDE THE MATURATION OF ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN HIV-INFECTED SUBJECTS | FRED HUTCHINSON CANCER CENTER (US) | 2024-02-15 | — | — | WO | disclosed |
| US-11896655-B2 | Circumsporozoite proteins with increased expression in mammalian cells | FRED HUTCHINSON CANCER CENTER (US) | 2024-02-13 | — | — | US | disclosed |
| US-11883485-B2 | Methods of eliciting antibodies that bind to full-length glycosylated HIV-1 Env using multimerized Env cores | FRED HUTCHINSON CANCER CENTER (US) | 2024-01-30 | — | — | US | disclosed |
| US-20220280626-A1 | CIRCUMSPOROZOITE PROTEINS WITH INCREASED EXPRESSION IN MAMMALIAN CELLS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551549-B2 | Methods of eliciting antibodies that bind to full-length glycosylated HIV-1 ENV using multimerized ENV cores | CD4, VSIG8, FCGR3B | PTGS1 4705/4885GSTK1 4694/4885MAPT 4125/4885 |
| US-11896655-B2 | Circumsporozoite proteins with increased expression in mammalian cells | RNGTT, CD2BP2, CSPP1 | PTGS1 3624/4885GSTK1 2563/4885MAPT 3015/4885 |
| US-20220280626-A1 | CIRCUMSPOROZOITE PROTEINS WITH INCREASED EXPRESSION IN MAMMALIAN CELLS | RNGTT, CD2BP2, CSPP1 | PTGS1 3624/4885GSTK1 2563/4885MAPT 3015/4885 |
| US-20240075121-A1 | CIRCUMSPOROZOITE PROTEINS WITH INCREASED EXPRESSION IN MAMMALIAN CELLS | RNGTT, CD2BP2, CSPP1 | PTGS1 3624/4885GSTK1 2563/4885MAPT 3015/4885 |
| US-20260041758-A1 | IMMUNIZATION STRATEGIES TO MORE NATURALLY GUIDE THE MATURATION OF ANTIBODIES AGAINST HUMAN IMMMUNODEFICIENCY VIRUS (HIV) IN HIV-INFECTED SUBJECTS | CD4, IGSF11, ICOS | PTGS1 4798/4885GSTK1 4247/4885MAPT 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.